Welcome to the ePoster Viewing Panel of AICOG 2025

Introduction (30 words) Physiological changes during pregnancy can significantly affect the pharmacokinetics of drugs. Hence, careful selection of the antihypertensive drug is important for maternal and fetal safety when managing pregnancy-induced hypertension (PIH). Aims and Objectives (Limit 40 words) Labetolol, hydralazine, and nifedipine are recommended by guidelines for the treatment of severe/urgent and non-severe/non-urgent PIH. However, few studies have evaluated the safety and efficacy of hydralazine in this population. We investigated the effect of hydralazine in Indian women with PIH. Material and Methods (Limit 80 words) We prospectively collected the data of pregnant women diagnosed and treated for PIH at 2 centers in Mumbai. Patients newly diagnosed with PIH were prescribed hydralazine monotherapy while those with uncontrolled PIH despite ongoing therapy received hydralazine as add-on therapy. The initial dose of hydralazine was 100 mg per day which was increased up to a maximum dose of 300 mg per day if necessary. Nifedipine was added if the blood pressure remained uncontrolled despite a maximum dose of hydralazine. Results (Limit 80 words) 92 women with a mean gestational age of 31.7 weeks were included. 14 were newly diagnosed while 78 were already on treatment for PIH. Among these, 72 were on labetolol (mean dose of 171 mg/day). The mean systolic and diastolic BP reduced from 156.5 and 101.35 mmg Hg respectively, to 101.35 and 66.5 mmHg respectively after initiation of hydralazine. The mean gestational age at delivery was 36.1 weeks, mean fetal birth weight was 2.65 kg, and mean 1-minute Apgar score was 7.1. Six patients required additional nifedipine treatment and one woman developed pre-eclampsia. There were no fetal abnormalities or deaths. One patient required Cesarean section. Conclusions (Limit 70 words) Hydralazine is safe and effective in the management of treatment-na?ve PIH as well as PIH not responding to previous treatment.